Epoch/Specialty launch leukaemia test:
This article was originally published in Clinica
Executive Summary
The first product to emerge from the partnership between molecular diagnostics company Epoch Biosciences (Bothell, Washington) and reference laboratory Specialty Laboratories (see Clinica No 910, p 13) is now commercially available. The BCR/ABL UltraQuant by MGB PCR test incorporates Epoch's proprietary Minor Groove Binder technology, and is used to identify residual leukaemia cells after radiation treatment and chemotherapy, and for monitoring drug therapy over time. The companies claim that the test is up to 3,000 times as sensitive as traditional bcr/abl PCR tests, which improves the physician's ability to detect early signs of and relapse.
You may also be interested in...
Mustang Bio Enters Race For CAR-T In Autoimmune Disease
The biotech company’s CEO talked to Scrip about plans to bring the CD20-targeting CAR-T MB-106 into an investigator-sponsored Phase I trial later this year.
Aldeyra Hopes To Refile Dry Eye Drug Reproxalap Later In 2024
Following an FDA complete response letter last November, Aldeyra has agreed with the agency on a trial design to demonstrate efficacy in ocular discomfort, which the company can complete this year.
Colorado Price Cap Plan For Enbrel Draws Amgen Lawsuit; Cosentyx, Stelara ‘Affordability’ Reviews Pending
However, the state's recently formed prescription drug affordability board found Gilead’s Genvoya and Vertex’s Trikafta to be affordable.